The 24th JFCR-ISCC
New Drugs in Development in Japan, Europe and the USA

2019 December 11 (Wed) 12:50 -19:20
December 12 (Thu) 9:00 -17:50

Miraikan
National Museum of Emerging Science and Innovation
2-3-6, Aomi, Koto-ku, Tokyo, Japan

Dec. 11 (Wed)

Session 1 — 13:00 -

New drugs under clinical or preclinical investigations (1)

Martijn P. Lolkema *Erasmus Univ.*
Clinical activity, safety, and PK/PD from a Phase 1 study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v): can we revive IL2 for cancer treatment?

Eijiro Nakamura *Kyoto Univ.*
Targeting HIF-2: the novel and ideal approach for the treatment of renal cell carcinoma and VHL-related tumors

Miles Congreve *Sosei Heptares*
Discovery of A2AR antagonist HTL1071/AZD4635 using SBDD

Session 2 — 15:15 -

Microbiome in tumorigenesis

Weiping Zou *Univ. Michigan*
CD8+ T cell-mediated regulation of tumor ferroptosis

Shinji Fukuda *Keio Univ.*
The impact of gut microbiota-derived metabolites in tumorigenesis

Meet-the-Expert Session

16:30 - **"PleSSision"; a pathologist edited cancer gene profiling test promotes cancer precision medicine in Japan**

Hiroshi Nishihara *Keio Univ*

17:10 - **Poster Flash Talks**
17:50 - **Poster Session & Mixer**

Dec. 12 (Thu)

Session 3 — 9:00 -

Tumor heterogeneity and resistance to TKI

Supported by MEXT Grant-in-Aid for Scientific Research on Innovative Areas
"Integrated Analysis and Regulation of Cellular Diversity (4904)"

Hiromichi Ebi *Aichi Cancer Ctr.*
Combinatorial treatments for tumors with aberrant MAPK signaling

Ryan Corcoran *MGH*
Therapeutic strategies to overcome resistance in BRAFV600E colorectal cancer

Seiji Yano *Kanazawa Univ.*
Drug-tolerant persister cells and AXL

11:00 - **Poster Discussion Session**

Luncheon Seminar

12:00 - Supported by TOPPAN

New drug screening system of anticancer agents by Ex vivo 3D culture technology

Eiji Shinozaki *JFCR*

Special Lecture

13:10 -

Benefits and risks of early marketing approval of novel anticancer drugs

Jaap Verweij *Erasmus Univ.*

Session 4 — 14:40 -

Molecular mechanisms underlying immunotherapy response

Sergio Quezada *UCL Cancer Inst.*
Targeting regulatory T cells in cancer: From mechanisms to new therapies

Ryohei Katayama *JFCR*
Diverse resistance mechanisms to anti-PD-L1 blockade therapy in cancer

Kohei Shitara *NCC Hospital East*
Immune checkpoint blockade and its combination therapy for GI cancers: Targeting the Immune Microenvironment

Session 5 — 16:20 -

New drugs under clinical or preclinical investigations (2)

Erkut Bahceci *Astellas Pharma Global Development*
Development of a small molecule FLT3 inhibitor in AML

Tatsuro Watanabe *Saga Univ.*
Development of novel orally bioavailable hypomethylating agents

Contact : Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
jfcr-iscc@ml.jfcr.or.jp

http://iscc.umin.jp/

The 24th JFCR-ISCC is supported by following companies: Bristol-Myers Squibb K.K., Kyowa Kirin Co., Ltd., Taiho Pharmaceutical Co., Ltd., AbbVie Inc., Astellas Pharma Inc., Biogen Japan Ltd., Celgene K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., FUJIFILM Corporation, MSD K.K., OHARA Pharmaceutical Co., Ltd. and Ono Pharmaceutical Co., Ltd.